Skip to main content
Login
Contact
Subscribe
Search form
Search
The Borger News-Herald
Home
Forms
News
Sports
Obituaries
Classifieds
Place an Ad
Classified Display Ads
Service Directory
Photos
Videos
Games
Entertainment
Calendar
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
Dow Jones Industrial Average
Nasdaq Composite
Standard & Poors 500
New York Composite
Gold
Crude Oil
Markets
Stocks
Funds
Tools
Overview
News
Currencies
International
Treasuries
Aptinyx Inc
(NQ:
APTX
)
3.340
USD
-0.170 (-4.84%)
Streaming Delayed Price
Updated: 10:58 AM EST, Mar 4, 2021
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Press releases about Aptinyx Inc
< Previous
1
2
3
Next >
Aptinyx to Report Fourth Quarter and Full Year 2020 Financial Results on Wednesday, March 24, 2021
March 02, 2021
Aptinyx Inc. (Nasdaq: APTX), a clinical-stage biopharmaceutical company developing transformative therapies for the treatment of brain and nervous system disorders, today announced that the company...
From
Business Wire News Releases
Aptinyx to Participate in Upcoming Investor Conferences
February 22, 2021
Aptinyx Inc. (Nasdaq: APTX), a clinical-stage biopharmaceutical company developing transformative therapies for the treatment of brain and nervous system disorders, today announced that company...
From
Business Wire News Releases
Aptinyx to Participate at 10th Annual SVB Leerink Global Healthcare Conference
February 11, 2021
Aptinyx Inc. (Nasdaq: APTX), a clinical-stage biopharmaceutical company developing transformative therapies for the treatment of brain and nervous system disorders, today announced that company...
From
Business Wire News Releases
Aptinyx Announces Publication of Review Article Highlighting Preclinical Data in Medicine in Drug Discovery Demonstrating the Potential of NYX-2925 to Treat Chronic, Centralized Pain Conditions
January 19, 2021
Aptinyx Inc. (Nasdaq: APTX), a clinical-stage biopharmaceutical company developing transformative therapies for the treatment of brain and nervous system disorders, today announced the publication of a...
From
Business Wire News Releases
Aptinyx to Participate in H.C. Wainwright BioConnect 2021 Conference
January 05, 2021
Aptinyx Inc. (Nasdaq: APTX), a clinical-stage biopharmaceutical company developing transformative therapies for the treatment of brain and nervous system disorders, today announced that company...
From
Business Wire News Releases
Aptinyx Announces Recommencement of Phase 2 Study of NYX-2925 in Patients With Painful Diabetic Peripheral Neuropathy
January 04, 2021
Aptinyx Inc. (Nasdaq: APTX), a clinical-stage biopharmaceutical company developing transformative therapies for the treatment of brain and nervous system disorders, today announced that in December it...
From
Business Wire News Releases
Aptinyx to Present at the 39th Annual J.P. Morgan Healthcare Conference
December 21, 2020
Aptinyx Inc. (Nasdaq: APTX), a clinical-stage biopharmaceutical company developing transformative therapies for the treatment of brain and nervous system disorders, today announced that the company...
From
Business Wire News Releases
Aptinyx Appoints Andy Kidd, M.D., President and Chief Operating Officer
December 16, 2020
Aptinyx Inc. (Nasdaq: APTX), a clinical-stage biopharmaceutical company developing transformative therapies for the treatment of brain and nervous system disorders, today announced the appointment of...
From
Business Wire News Releases
Aptinyx Reports Third Quarter 2020 Financial Results and Recent Highlights
November 12, 2020
Aptinyx Inc. (Nasdaq: APTX), a clinical-stage biopharmaceutical company developing transformative therapies for the treatment of brain and nervous system disorders, today reported financial results for...
From
Business Wire News Releases
Aptinyx to Participate in Upcoming Virtual Investor Conferences
November 10, 2020
EVANSTON, Ill., November 10, 2020 – Aptinyx Inc. (Nasdaq: APTX), a clinical-stage biopharmaceutical company developing transformative therapies for the treatment of brain and nervous system disorders,...
From
Business Wire News Releases
Aptinyx to Report Third Quarter Financial Results on Thursday, November 12, 2020
October 29, 2020
Aptinyx Inc. (Nasdaq: APTX), a clinical-stage biopharmaceutical company developing transformative therapies for the treatment of brain and nervous system disorders, today announced that the company...
From
Business Wire News Releases
Aptinyx Announces Closing of Public Offering of Common Stock and Full Exercise of Underwriters’ Option
October 26, 2020
Aptinyx Inc. (Nasdaq: APTX), a clinical-stage biopharmaceutical company developing transformative therapies for the treatment of brain and nervous system disorders, today announced the closing of its...
From
Business Wire News Releases
Aptinyx Announces Pricing of Public Offering of Common Stock
October 21, 2020
Aptinyx Inc. (Nasdaq: APTX), a clinical-stage biopharmaceutical company developing transformative therapies for the treatment of brain and nervous system disorders, today announced the pricing of its...
From
Business Wire News Releases
Aptinyx Announces Proposed Public Offering of Common Stock
October 20, 2020
Aptinyx Inc. (Nasdaq: APTX), a clinical-stage biopharmaceutical company developing transformative therapies for the treatment of brain and nervous system disorders, today announced that it intends to...
From
Business Wire News Releases
Thinking about buying stock in Aptinyx, Acorda Therapeutics, T-Mobile, Best Buy, or Advanced Micro Devices?
October 20, 2020
InvestorsObserver issues critical PriceWatch Alerts for APTX, ACOR, TMUS, BBY, and AMD.
From
PR Newswire
Aptinyx Reports Positive, Statistically Significant, Top-line Data From Phase 2 Study of NYX-783 in Patients With Post-Traumatic Stress Disorder
October 19, 2020
Aptinyx Inc. (Nasdaq: APTX), a clinical-stage biopharmaceutical company developing transformative therapies for the treatment of brain and nervous system disorders, today announced positive results...
From
Business Wire News Releases
Aptinyx Recommences Patient Recruitment in Phase 2 Study of NYX-2925 in Patients with Fibromyalgia
September 28, 2020
Aptinyx Inc. (Nasdaq: APTX), a clinical-stage biopharmaceutical company developing transformative therapies for the treatment of brain and nervous system disorders, today announced that it has...
From
Business Wire News Releases
Aptinyx to Present at Upcoming Virtual Investor Conferences
September 03, 2020
Aptinyx Inc. (Nasdaq: APTX), a clinical-stage biopharmaceutical company developing transformative therapies for the treatment of brain and nervous system disorders, today announced that company...
From
Business Wire News Releases
Aptinyx Reports Second Quarter 2020 Financial Results and Highlights
August 13, 2020
Aptinyx Inc. (Nasdaq: APTX), a clinical-stage biopharmaceutical company developing transformative therapies for the treatment of brain and nervous system disorders, today reported financial results for...
From
Business Wire News Releases
Aptinyx to Present at the 2020 Wedbush PacGrow Healthcare Virtual Conference
August 04, 2020
Aptinyx Inc. (Nasdaq: APTX), a clinical-stage biopharmaceutical company developing transformative therapies for the treatment of brain and nervous system disorders, today announced that company...
From
Business Wire News Releases
Aptinyx to Report Second Quarter Financial Results on Thursday, August 13, 2020
July 30, 2020
Aptinyx Inc. (Nasdaq: APTX), a clinical-stage biopharmaceutical company developing transformative therapies for the treatment of brain and nervous system disorders, today announced that the company...
From
Business Wire News Releases
Aptinyx to Host PTSD-Focused R&D Day on August 5th, 2020
July 08, 2020
Aptinyx Inc. (Nasdaq: APTX), a clinical-stage biopharmaceutical company developing transformative therapies for the treatment of brain and nervous system disorders, today announced that it will host a...
From
Business Wire News Releases
Aptinyx to be Added to Russell 2000® Index
June 26, 2020
Aptinyx Inc. (Nasdaq: APTX), a clinical-stage biopharmaceutical company developing transformative therapies for the treatment of brain and nervous system disorders, will be added as a member of the US...
From
Business Wire News Releases
Aptinyx Completes Enrollment in Phase 2 Exploratory Study of NYX-783 in Post-Traumatic Stress Disorder
June 18, 2020
Data readout expected by late 2020
From
GlobeNewswire News Releases
Aptinyx to Present at Upcoming Virtual Investor Conferences
June 16, 2020
From
GlobeNewswire News Releases
Aptinyx Reports First Quarter 2020 Financial Results and Highlights
May 14, 2020
From
GlobeNewswire News Releases
NASDAQ:APTX Shareholder Notice: Investigation over Potential Wrongdoing at Aptinyx Inc.
May 12, 2020
San Diego, CA -- (SBWIRE) -- 05/12/2020 -- An investigation was announced over potential breaches of fiduciary duties by certain officers and directors at Aptinyx Inc.
From
SBWire - Latest Press Releases
Aptinyx to Report First Quarter Financial Results on Thursday, May 14, 2020
April 30, 2020
From
GlobeNewswire News Releases
Aptinyx Reports Fourth Quarter and Full Year 2019 Financial Results and Provides Corporate Update
March 30, 2020
From
GlobeNewswire News Releases
Aptinyx to Report Fourth Quarter and Full Year 2019 Financial Results on Monday, March 30, 2020
March 18, 2020
From
GlobeNewswire News Releases
< Previous
1
2
3
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.
